tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

FOLD Stock Latest News

Amicus price target raised to $19 from $18 at JPMorgan
The FlyAmicus price target raised to $19 from $18 at JPMorgan
5d ago
FOLD
Amicus price target raised to $11 from $9 at Goldman Sachs
PremiumThe Fly
Amicus price target raised to $11 from $9 at Goldman Sachs
6d ago
FOLD
Amicus Therapeutics Reports Strong Q3 2025 Results
PremiumCompany Announcements
Amicus Therapeutics Reports Strong Q3 2025 Results
6d ago
FOLD
Amicus Therapeutics Reports Strong Q3 Earnings Growth
PremiumCompany Announcements
Amicus Therapeutics Reports Strong Q3 Earnings Growth
6d ago
FOLD
Amicus’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Analyst
PremiumRatings
Amicus’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Analyst
6d ago
FOLD
Amicus Therapeutics: Strong Q3 Performance and Strategic Advancements Justify Buy Rating
PremiumRatingsAmicus Therapeutics: Strong Q3 Performance and Strategic Advancements Justify Buy Rating
6d ago
FOLD
Amicus reports Q3 non-GAAP EPS 17c, consensus 12c
Premium
The Fly
Amicus reports Q3 non-GAAP EPS 17c, consensus 12c
7d ago
FOLD
Amicus anticipates surpassing $1B in sales in 2028
Premium
The Fly
Amicus anticipates surpassing $1B in sales in 2028
7d ago
FOLD
Amicus sees FY25 total revenue growth 15%-22%
PremiumThe Fly
Amicus sees FY25 total revenue growth 15%-22%
7d ago
FOLD
FOLD Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
FOLD Upcoming Earnings Report: What to Expect?
9d ago
FOLD
Target initiated, Nike upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Target initiated, Nike upgraded: Wall Street’s top analyst calls
2M ago
DG
HD
Needham upgrades Amicus to Buy on reduced regulatory risk
PremiumThe Fly
Needham upgrades Amicus to Buy on reduced regulatory risk
2M ago
FOLD
Amicus Stock Upgraded to Buy: DMX-200’s Potential and Galafold’s Growth Drive Investment Opportunity
PremiumRatingsAmicus Stock Upgraded to Buy: DMX-200’s Potential and Galafold’s Growth Drive Investment Opportunity
2M ago
FOLD
Amicus upgraded to Buy from Hold at Needham
Premium
The Fly
Amicus upgraded to Buy from Hold at Needham
2M ago
FOLD
Positive Outlook for Amicus Therapeutics Amid Legal Developments and Patent Confidence
Premium
Ratings
Positive Outlook for Amicus Therapeutics Amid Legal Developments and Patent Confidence
2M ago
FOLD
Jefferies says Galafold summary judgment as expected, may facilitate settlement
PremiumThe Fly
Jefferies says Galafold summary judgment as expected, may facilitate settlement
2M ago
FOLD
Amicus presents four-year data from PROPEL study of Pombiliti, Opfolda
PremiumThe Fly
Amicus presents four-year data from PROPEL study of Pombiliti, Opfolda
2M ago
FOLD
Amicus Therapeutics’ Pompe Disease Study: A Potential Game-Changer for Investors
PremiumCompany Announcements
Amicus Therapeutics’ Pompe Disease Study: A Potential Game-Changer for Investors
2M ago
FOLD
Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer
PremiumCompany Announcements
Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer
3M ago
FOLD
Amicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer
PremiumCompany AnnouncementsAmicus Therapeutics’ Global Study on Pompe Disease: A Potential Game-Changer
3M ago
FOLD
Amicus’s Strong Performance and Growth Potential Drive Buy Rating
Premium
Ratings
Amicus’s Strong Performance and Growth Potential Drive Buy Rating
3M ago
FOLD
Amicus price target raised to $18 from $16 at JPMorgan
Premium
The Fly
Amicus price target raised to $18 from $16 at JPMorgan
3M ago
FOLD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >